Business
Satellos Bioscience Co-Founder and Chief Scientific Officer Awarded Prestigious Defeat Duchenne Canada 2022 Grant
Toronto, Ontario--(Newsfile Corp. - June 17, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience Co-Founder and Chief Scientific Officer Awarded Prestigious Defeat Duchenne Canada 2022 GrantToronto, Ontario--(Newsfile Corp. - June 17, 2022) - Satellos Bioscience Inc. (TSXV: MSCL) (\"Satellos\" or the \"Company\"), a regenerative medicine company aimed at developing therapeutics that change the way degenerative muscle diseases are treated, announced today that Co-founder and Chief Scientific Officer Dr. Michael Rudnicki has been named one of only three 2022 recipients of a prestigious grant awarded from Defeat Duchenne Canada, the country's only national charity dedicated to ending Duchenne muscular dystrophy (\"Duchenne\"). \"We're very excited for Michael and his academic team at the Ottawa Hospital Research Institute (\"OHRI\") as they continue to develop game changing science that can greatly improve the quality of treatment and life for those with Duchenne and other muscular dystrophies,\" said Satellos Co-Founder and CEO, Frank Gleeson. \"This type of grant funding is key in supporting Canada's research ecosytem by enabling translational research and advancement of new discoveries with potential to help patients. We applaud Defeat Duchene Canada for its leadership, ongoing support and visionary investments in developing innovative science for the fight against Duchenne.\" The grant, awarded to the OHRI where Dr. Rudnicki is based, is for his discovery of a protein called Wnt7a and its role in stem cell division and potentially, as a treatment for Duchenne. Satellos has exclusively licensed rights to a portfolio of granted patents and patent applications related to Wnt7a from the OHRI as the Company believes Wnt7a has therapeutic potential. Defeat Duchenne Canada, previously known as Jesse's Journey, has provided more than $16M in funding over its 27-year history which includes financial support in prior years to both Satellos and Dr. Rudnicki. \"Support over the years from Defeat Duchenne Canada has been critical to enabling my lab at OHRI to pursue innovative ideas for treating Duchenne - many of which may have application to other muscle disorders. This new grant to further our work on the systemic delivery of Wnt7a as a potential protein therapeutic has the potential to create proof of concept and underpin a future second development program in Satellos, a key aim. I would like to thank Defeat Du...